Emerging treatments
Newer broad-spectrum antibacterial agents
Contemporary and emerging therapeutic options for the treatment of gram-positive organisms include ceftaroline, telavancin, dalbavancin, oritavancin, and delafloxacin. Broad-spectrum agents or agents primarily active against gram-negative pathogens include ceftazidime/avibactam, ceftolazane/tazobactam, meropenem/vaborbactam, imipenem/relebactam, cefiderocol, eravacycline, and plazomicin. There are emerging reports of use of these agents for targeted treatment in neutropenic patients with bacteremia, but studies investigating their use for empiric management of febrile neutropenia are lacking.[90]
Use of this content is subject to our disclaimer